Abrahamsen 1995.

Clinical features and settings	Inclusion period: September 1984 to December 1993. Patient population: 36 patients with suspected neuroblastoma and125 ¹²³I‐ and ¹³¹I‐MIBG scans Consecutive series: yes. Diagnostic work‐up: standard investigations like CT and US. Time spans symptoms‐index test, symptoms‐reference standard and index test‐reference standard: n.r. Treatment between index test‐reference standard: n.r.
Participants	Included patients: 36 children with suspected neuroblastoma and a ¹²³I‐ or ¹³¹I‐MIBG scan at diagnosis; in 19 patients the diagnosis was confirmed by histopathology, in 17 patients it was not. Median age at diagnosis: n.r.for patients with ¹²³I‐MIBG scans separate from those with ¹³¹I‐MIBG scans; for all 36 patients: 2 years and 10 months (range 1 month to 14 years and 10 months); for the 19 patients with confirmed neuroblastoma at first diagnosis: 2 years and 9 months (range 1 to 10 years and 10 months); for the 17 patients without neuroblastoma: 2 years and 10.5 months (range 9 months to 14 years and 10 months). Sex distribution: 20 boys (56%), 16 girls (44%); for the 19 patients with confirmed neuroblastoma at first diagnosis: 9 boys (47%), 10 girls (53%); for the 17 patients without neuroblastoma: 11 boys (65%), 6 girls (35%). INSS stage for the 19 patients with confirmed neuroblastoma: 1 patient stage 1, 7 patients stage 3, 8 patients stage 4 and 3 patients stage 4S.
Study design	Retrospective cohort study.
Target condition and reference standard(s)	Target condition: newly diagnosed neuroblastoma. Reference standard: histopathology in 19 patients.
Index and comparator tests	Index test: ¹²³I‐MIBG and ¹³¹I‐scintigraphy. Radiofarmacon: ¹²³I‐ and ¹³¹I‐MIBG. Dose: 74 MBq for children weighing less than 8 kg, 111 MBq for children weighing more than 20 kg and 185 MBq for children weighing more than 20 kg. Collimator: n.r. Matrix: 64 x 64. Acquisition protocol: anterior and posterior images of the head and the whole truncus. Acquisition time: 4, 24 and 48 hours after injection. Acquisition duration: 300 seconds, 300,000 to 400,000 counts. Interfering medication: n.r. Thyroid prophylaxis: supersaturated potassium iodide twice daily starting one day before the examination and for three days. Positive test result: the level of tumour uptake similar to or higher than that in the salivary glands, myocardium and liver. Number of observers: ¹²³I‐MIBG scans were interpreted by one specialist, without knowledge of the diagnosis at the time of the first ¹²³I‐MIBG scan. Expertise of observers: n.r. Interobserver concordance: n.r.
Follow‐up	n.r.
Notes	Results not reported for ¹²³I‐MIBG scans separately from the ¹³¹I‐MIBG scans. Contact information of the authors: not available.